Please use this identifier to cite or link to this item:
10.3389/fimmu.2022.928945
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grāvelsiņa, Sabīne | - |
dc.contributor.author | Vilmane, Anda | - |
dc.contributor.author | Svirskis, Simons | - |
dc.contributor.author | Rasa-Dzelzkaleja, Santa | - |
dc.contributor.author | Nora-Krūkle, Zaiga | - |
dc.contributor.author | Vecvagare, Katrine | - |
dc.contributor.author | Krumina, Angelika | - |
dc.contributor.author | Leineman, Iana | - |
dc.contributor.author | Shoenfeld, Yehuda | - |
dc.contributor.author | Murovska, Modra | - |
dc.date.accessioned | 2022-10-31T09:00:02Z | - |
dc.date.available | 2022-10-31T09:00:02Z | - |
dc.date.issued | 2022-10-10 | - |
dc.identifier.citation | Grāvelsiņa , S , Vilmane , A , Svirskis , S , Rasa-Dzelzkaleja , S , Nora-Krūkle , Z , Vecvagare , K , Krumina , A , Leineman , I , Shoenfeld , Y & Murovska , M 2022 , ' Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome ' , Frontiers in Immunology , vol. 13 , 928945 . https://doi.org/10.3389/fimmu.2022.928945 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/9685 | - |
dc.description | Funding Information: This research was funded by EU H2020 project VirA, No.952376 and by the Latvian Science Council’s Fundamental and Applied Research project Nr. LZP-2019/1-0380. Publisher Copyright: Copyright © 2022 Gravelsina, Vilmane, Svirskis, Rasa-Dzelzkaleja, Nora-Krukle, Vecvagare, Krumina, Leineman, Shoenfeld and Murovska. | - |
dc.description.abstract | Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease that is mainly diagnosed based on its clinical symptoms. Biomarkers that could facilitate the diagnosis of ME/CFS are not yet available; therefore, reliable and clinically useful disease indicators are of high importance. The aim of this work was to analyze the association between ME/CFS clinical course severity, presence of HHV-6A/B infection markers, and plasma levels of autoantibodies against adrenergic and muscarinic acetylcholine receptors. A total of 134 patients with ME/CFS and 33 healthy controls were analyzed for the presence of HHV-6A/B using PCRs, and antibodies against beta2-adrenergic receptors (β2AdR) and muscarinic acetylcholine receptors (M3 AChR and M4 AChR) using ELISAs. HHV-6A/B U3 genomic sequence in whole-blood DNA was detected in 19/31 patients with severe ME/CFS, in 18/73 moderate ME/CFS cases, and in 7/30 mild ME/CFS cases. Severity-related differences were found among those with a virus load of more than 1,000 copies/106 PBMCs. Although no disease severity-related differences in anti-β2AdR levels were observed in ME/CFS patients, the median concentration of these antibodies in plasma samples of ME/CFS patients was 1.4 ng/ml, while in healthy controls, it was 0.81 ng/ml, with a statistically significant increased level in those with ME/CFS (p = 0.0103). A significant difference of antibodies against M4 AChR median concentration was found between ME/CFS patients (8.15 ng/ml) and healthy controls (6.45 ng/ml) (p = 0.0250). The levels of anti-M4 plotted against disease severity did not show any difference; however, increased viral load correlates with the increase in anti-M4 level. ME/CFS patients with high HHV-6 load have a more severe course of the disease, thus confirming that the severity of the disease depends on the viral load—the course of the disease is more severe with a higher viral load. An increase in anti-M4 AchR and anti-β2AdR levels is detected in all ME/CFS patient groups in comparison to the control group not depending on ME/CFS clinical course severity. However, the increase in HHV-6 load correlates with the increase in anti-M4 level, and the increase in anti-M4 level, in turn, is associated with the increase in anti-β2AdR level. Elevated levels of antibodies against β2AdR and M4 receptors in ME/CFS patients support their usage as clinical biomarkers in the diagnostic algorithm of ME/CFS. | en |
dc.format.extent | 4938943 | - |
dc.language.iso | eng | - |
dc.relation.ispartof | Frontiers in Immunology | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | ME/CFS | - |
dc.subject | b2AdR antibodies | - |
dc.subject | AChR antibodies , HHV-6, biomarkers | - |
dc.subject | HHV-6 | - |
dc.subject | biomarkers | - |
dc.subject | Fatigue Syndrome | - |
dc.subject | AChR antibodies | - |
dc.subject | β2AdR antibodies | - |
dc.subject | 3.1 Basic medicine | - |
dc.subject | 3.2 Clinical medicine | - |
dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | - |
dc.subject | General Medicine | - |
dc.subject | Immunology and Allergy | - |
dc.subject | Immunology | - |
dc.title | Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome | en |
dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article | - |
dc.identifier.doi | 10.3389/fimmu.2022.928945 | - |
dc.contributor.institution | Institute of Microbiology and Virology | - |
dc.contributor.institution | Department of Infectology | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85140287340&partnerID=8YFLogxK | - |
dc.description.status | Peer reviewed | - |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
fimmu_13_928945_5_.pdf | 4.82 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.